Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Deltex Medical Hails Strong Oesophageal Doppler Monitoring Trials

1st Jun 2016 07:23

LONDON (Alliance News) - Deltex Medical Group PLC on Wednesday said the largest-ever multi-centre oesophageal Doppler monitoring technology trial has delivered very strong results, indicating a reduction in post-surgery complications.

Deltex, which makes oesophageal Doppler monitoring probes, said the trial, carried out by a group of doctors in Spain, showed a 72% reduction in post-operative complications.

In addition, the results showed a statistically-significant reduction in five types of major complication, including acute kidney injury, pneumonia, superficial surgical site infection, deep surgical site infection and cardiopulmonary oedema.

"These are superb results from the largest ever ODM randomised controlled trial. They confirm the unique ability of ODM to help doctors eliminate more than half of dangerous complications after surgery," said Deltex Chief Executive Ewan Phillips.

Deltex shares were up 13% on the news to 4.95 pence Wednesday.

By Sam Unsted; [email protected]; @SamUAtAlliance

Copyright 2016 Alliance News Limited. All Rights Reserved.


Related Shares:

Deltex Medical
FTSE 100 Latest
Value8,809.74
Change53.53